| Name
|
Dermorphin Analog
|
| Other Name
|
Dermorphin Analog
|
| Sequence (Single letter abbreviations)
|
|
| Sequence（Three letter abbreviations）
|
TYR-d-ARG-PHE-SAR-TYR-PRO-SER-NH2
|
| C-port
|
NH2
|
| Basic description
|
The dermorphin-derived peptide [Dmt1] dermorphin analog labels m-opioid receptors with affinity and selectivity in receptor binding assays. In mice, radiant heat tail-flick assays, [Dmt1] dermorphin analog produces profound spinal and supraspinal analgesia, being approximately 5000 and 100 times more potent respectively than morphine in causing these analgesia on a molar basis. When administered systemically, [Dmt1] dermorphin analog has been shown to be over 200 times more potent than morphine.
|
| Solubility
|
Dermorphin analog is soluble in water. The contents of this vial have been accurately determined. Both the stopper and the vial have been siliconized. Do not attempt to weigh out a smaller portion of the contents.
|
| The molecular weight
|
901.430
|
| Chemical formula
|
C44H59N11O10
|
| The purity
|
> 95%
|
| Storage conditions
|
Before use, store dermorphin analog in the DRY form at 0-5°C. For and more repeatable results, rehydrate the peptide immediately before use. Do not re-freeze any unused portions.
|
| Documents
|
|
| Figures
|
|
| Reference
|
Buczek O, et al. Characterization of D-amino-acid-containing excitatory conotoxins and redefinition of the I-conotoxin superfamily. FEBS J. Aug 2005;272(16):4178-4188.
|
HIV-I TAT Protein Peptide
